Esraa A. Aldkheil

Ms. Esraa A. Aldkheil


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
NMNahed Mahrous
Nahed Mahrous
MFMohannad M. Fallatah
Mohannad M. Fallatah
RFRawan Fitaihi
Rawan Fitaihi
HAHala Aldahshan
Hala Aldahshan
AAAreej Alhhazmi
Areej Alhhazmi
Yahya F. JamousYahya F. Jamous
Yahya F. Jamous
Antimicrobial resistance (AMR) is an ever-growing threat to global healthcare. It is largely driven by delayed or inadequate pathogen identification and antimicrobial susceptibility testing in routine clinical workflows. By the time the clinician receives results to guide treatment from traditional culture-based diagnostics, several days may have elapsed, leading to the use and potential over-prescription of broad-spectrum antibiotics and the development of resistant pathogens. A rapid and clinically actionable diagnostic approach at the clinical point of care (POC) may help address this gap. This review examines current and emerging POC diagnostic technologies for AMR and outlines the fundamental principles and mechanistic classifications of POC diagnostic technologies. These include phenotypic, genotypic, immunological, and biosensor-based approaches. A critical overview of key technological platforms, including rapid phenotypic antimicrobial susceptibility testing (AST), microfluidics and isothermal nucleic acid amplification (e.g., LAMP and RPA), CRISPR-based diagnostics, nanomaterial-enhanced biosensors, and mobile-integrated systems is provided. The impact of POC diagnostics on antimicrobial stewardship, time to appropriate therapy, and patient outcomes in primary care settings, hospitals, intensive care units, and resource-limited settings is presented and discussed. In addition to clinical implementation challenges, this review considers the issues of analytical performance, workflow, regulatory pathways, cost, and implementation readiness. In addition, it outlines key trends regarding digital integration, surveillance, workforce training, and policy frameworks. Overall, the review outlines the role of POC diagnostics in enhancing antimicrobial response surveillance and the global fight against AMR. Among emerging platforms, rapid phenotypic AST, microfluidic and isothermal-based assays, CRISPR-based diagnostics, and integrated biosensor systems show the greatest potential for near-term clinical impact; however, widespread implementation remains constrained by challenges related to clinical validation, cost, workflow integration, and alignment with antimicrobial stewardship frameworks.

23 July 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MFMohannad M. Fallatah
Mohannad M. Fallatah
SASAMIYAH ALKHALDI
SAMIYAH ALKHALDI
DADimah K Alrabiah
Dimah K Alrabiah
IAIbrahim Alradwan
Ibrahim Alradwan
MAMohammad Nasser Alkhrayef
Mohammad Nasser Alkhrayef
AAAhmad Mohammad Aldossary
Ahmad Mohammad Aldossary
RNA vaccines have emerged as an attractive platform for treating infectious diseases, cancer immunotherapy, and personalized medicine; however, their clinical success depends on multiple factors, including efficient, stable, and scalable delivery systems. Because RNA molecules are highly sensitive to factors such as enzymatic degradation, oxidation, poor cellular uptake, and limited endosomal escape, nanocarrier platforms play essential roles in protecting RNA cargo and enabling effective intracellular delivery. The biological performance of RNA nanocarriers depends on efficient cellular uptake, endosomal escape, intracellular RNA delivery, biodistribution, and immune modulation. Comparative assessment emphasizes that lipid nanoparticles remain the most clinically mature approach, while nanostructured lipid carriers, polymeric systems, and exosome-based nanocarriers provide multiple benefits for stability, targeted delivery, biocompatibility, and/or controlled release. Translational challenges involving GMP manufacturing, batch reproducibility, regulatory expectations, and scale-up are considered critical for effective nano-based RNA vaccine delivery and are elaborated in this review. Emerging advances such as pKa-tuned ionizable lipids, ligand-targeted systems, stimuli-responsive nanocarriers, circular and self-amplifying RNA platforms, artificial intelligence-guided formulation design, and needle-free delivery technologies may further expand the safety, accessibility, and therapeutic potential of RNA vaccines. In this review, we highlight next-generation nanocarrier systems for RNA vaccines, with an emphasis on novel nanocarrier RNA vaccine delivery systems. Additionally, we evaluate stability engineering approaches that currently limit global vaccine distribution and the future of the nanocarrier platforms for RNA vaccines.

Verified
Journal Article
Open access
PDF file
YHYousef Hawsawi
Yousef Hawsawi
Yahya F. JamousYahya F. Jamous
Yahya F. Jamous
SAShouq Fahad Alghannam
Shouq Fahad Alghannam
HAHala Aldahshan
Hala Aldahshan
LALoulwah Alothman
Loulwah Alothman
SASarah S. Alotaibi
Sarah S. Alotaibi
Microgravity research has emerged as a rapidly evolving field at the intersection of space medicine, genomics, biotechnology, and precision medicine. Exposure to the space environment induces complex physiological and molecular adaptations that affect multiple biological systems, including immune regulation, metabolism, musculoskeletal function, and gene expression. Recent advances in genomics, multi-omics technologies, artificial intelligence, and bioengineering have substantially improved our understanding of biological adaptation to spaceflight and expanded opportunities for translational biomedical research. This review summarizes recent advances in genetic and biomedical research under microgravity conditions, with particular emphasis on molecular mechanisms, omics technologies, genome editing, microbiome research, regenerative medicine, and personalized healthcare approaches. Major experimental platforms, landmark spaceflight studies, and translational applications in infectious diseases, cancer biology, aging, tissue engineering, and pharmaceutical development are discussed. The review also highlights Saudi Arabia’s emerging contributions to genomic medicine and space biosciences through initiatives such as the Saudi Human Genome Program, the Saudi Pangenome Project, the Saudi Space Agency, and the BioGravity Initiative. Recent Saudi participation in human spaceflight and microgravity-associated biomedical research is discussed within the context of Vision 2030 and national investments in biotechnology and precision medicine. Collectively, advances in microgravity research are expected to contribute to the advancement of precision medicine and facilitate the development of innovative diagnostic and therapeutic strategies with significant implications for both human space exploration and terrestrial healthcare.

28 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
AAAreej Mohammed Alajmi
Areej Mohammed Alajmi
AAAbdullah Alshehri
Abdullah Alshehri
NFNojoud AL Fayez
Nojoud AL Fayez
FAFahad Almughem
Fahad Almughem
HAHaila M Alnassar
Haila M Alnassar
ETEssam Tawfik
Essam Tawfik
Antibiotic resistance poses a growing threat to public health, yet limited innovation and development of new antibacterial agents continue to hinder antibiotic discovery. Although only a few novel antibiotic candidates have passed clinical trials and reached the market, resistance continues to grow faster than antibiotic development. Despite numerous advances in drug development, using these technologies in isolation has constrained antibiotic discovery. This review examines how advanced technologies integrate into antibiotic drug discovery. It highlights a coupled approach (co-applied technologies) as an innovative strategy to mitigate the limitations of single approaches and accelerate lead discovery. By highlighting each technology and reviewing its potential applications, this strategy opens new routes and methods that can yield novel chemical scaffolds and new mechanisms of action (i.e., weakening microbial resistance), addressing the challenges posed by increasing global resistance and shortcomings in current antibiotic development. The review also addresses the challenges and barriers to discovering next-generation antibiotics. It also encourages researchers to implement platforms that combine coupled approaches and technologies, such as computational, genomic, biochemical, and structural tools, to replenish the next-generation antibiotic discovery pipeline and address the antimicrobial resistance (AMR) crisis. To strengthen global efforts and lessen the AMR crisis, an innovative antibiotic discovery strategy is necessary.